AR128475A1 - POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY - Google Patents

POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY

Info

Publication number
AR128475A1
AR128475A1 ARP230100294A ARP230100294A AR128475A1 AR 128475 A1 AR128475 A1 AR 128475A1 AR P230100294 A ARP230100294 A AR P230100294A AR P230100294 A ARP230100294 A AR P230100294A AR 128475 A1 AR128475 A1 AR 128475A1
Authority
AR
Argentina
Prior art keywords
polypeptide
tslp
binding
fusion protein
expression vector
Prior art date
Application number
ARP230100294A
Other languages
Spanish (es)
Inventor
Anna Edvardsson
Lindvi Gudmundsdotter
Siavash Kijani
Susanne Klint
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of AR128475A1 publication Critical patent/AR128475A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con una clase de polipéptidos obtenidos por ingeniería que tiene una afinidad de unión a la linfoproteína estromal tímica (TSLP) y proporciona un polipéptido de unión a TSLP que comprende la secuencia EAVX⁴ALX⁷EIWX¹¹LPNLX¹⁶X¹⁷X¹⁸QX²⁰X²¹AFIX²⁵X²⁶LRD o una secuencia que tiene al menos 93% de identidad con la misma. La presente descripción también ser relaciona con el uso de dicho polipéptido de unión a TSLP como un agente terapéutico, de pronóstico y/o de diagnóstico. Reivindicación 62: Polinucleótido que codifica un polipéptido de unión a TSLP o proteína de fusión de acuerdo con cualquier reivindicación precedente. Reivindicación 63: Vector de expresión que codifica un polinucleótido de acuerdo con la reivindicación 62. Reivindicación 64: Célula huésped que comprende un vector de expresión de acuerdo con la reivindicación 63. Reivindicación 65: Método de producción de un polipéptido, proteína de fusión o conjugado de acuerdo con una cualquiera de las reivindicaciones 1 - 60 que comprende cultivar una célula huésped de acuerdo con la reivindicación 64 bajo condiciones que permiten la expresión de dicho polipéptido a partir de dicho vector de expresión; y aislar dicho polipéptido. Reivindicación 66: Composición que comprende un polipéptido, proteína de fusión o conjugado de unión a TSLP de acuerdo con una cualquiera de las reivindicaciones 1 - 61 y al menos un excipiente o portador farmacéuticamente aceptable.The present disclosure relates to a class of engineered polypeptides having a binding affinity to thymic stromal lymphoprotein (TSLP) and provides a TSLP-binding polypeptide comprising the sequence EAVX⁴ALX⁷EIWX¹¹LPNLX¹⁶X¹⁷X¹⁸QX²⁰X²¹AFIX²⁵X²⁶LRD or a sequence having at least 93% of identity with it. The present description also relates to the use of said TSLP-binding polypeptide as a therapeutic, prognostic and/or diagnostic agent. Claim 62: Polynucleotide encoding a TSLP-binding polypeptide or fusion protein according to any preceding claim. Claim 63: Expression vector encoding a polynucleotide according to claim 62. Claim 64: Host cell comprising an expression vector according to claim 63. Claim 65: Method of producing a polypeptide, fusion protein or conjugate according to any one of claims 1-60 comprising culturing a host cell according to claim 64 under conditions that allow expression of said polypeptide from said expression vector; and isolating said polypeptide. Claim 66: Composition comprising a polypeptide, fusion protein or TSLP binding conjugate according to any one of claims 1-61 and at least one pharmaceutically acceptable excipient or carrier.

ARP230100294A 2022-02-08 2023-02-08 POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY AR128475A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22155646 2022-02-08

Publications (1)

Publication Number Publication Date
AR128475A1 true AR128475A1 (en) 2024-05-15

Family

ID=80682629

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100294A AR128475A1 (en) 2022-02-08 2023-02-08 POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY

Country Status (3)

Country Link
AR (1) AR128475A1 (en)
AU (1) AU2023218534A1 (en)
WO (1) WO2023152144A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
CN111763247A (en) 2012-09-25 2020-10-13 阿菲博迪公司 Albumin binding polypeptides
EP3154563B1 (en) 2014-06-13 2019-08-14 Affibody AB New polypeptide
MX2017008660A (en) * 2015-01-12 2017-11-17 Affibody Ab Il-17a-binding polypeptides.
EP3693378A1 (en) 2015-10-30 2020-08-12 Affibody AB New polypeptide having affinity to pd-l1
US20220389066A1 (en) * 2019-11-05 2022-12-08 Affibody Ab Polypeptides

Also Published As

Publication number Publication date
AU2023218534A1 (en) 2024-07-11
WO2023152144A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
PE20091931A1 (en) MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
AR055191A1 (en) GENERATION AND CHARACTERIZATION OF THERAPEUTIC ANTIBODIES DERIVED FROM HUCAL- GOLD FULLY HUMAN SPECIFIC FOR THE HUMAN CD38
JP2020502262A5 (en)
BR112022016657A2 (en) BCMA CAR-T CELLS WITH IMPROVED ACTIVITIES
MX2022007120A (en) Recombinant peptide-mhc complex binding proteins and their generation and use.
BR9813416A (en) Compositions and methods of recombinant nodaviruses
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
ATE449790T1 (en) RECOMBINANT GELATIN PARTICLES FOR CELL ADHESION
DK200601181A (en) fish vaccine
DE60131450D1 (en) HEFEEXPRESSION VECTOR AND METHOD FOR PRODUCING A RECOMBINANT PROTEIN BY EXPRESSION IN A HEFING CELL
BR112023003526A2 (en) IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS
WO2021116470A3 (en) Recombinant peptide-mhc complex binding proteins and their generation and use
BRPI0410562B8 (en) carrier protein and its production method in a plant, isolated nucleic acid, expression vector and host cell
AR083586A1 (en) FACTOR PEPTIDES VIII (FVIII) FOR IMMUNE TOLERANCE INDUCTION AND FOR IMMUNODIAGNOSIS
CL2023001434A1 (en) il-2 mutein; fusion protein; nucleic acid; vector; host cell; methods; use
WO2021252406A3 (en) Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof
WO2020188348A3 (en) A2/ny-eso-1 specific t cell receptors and uses thereof
MX2022014938A (en) Proteins comprising cd3 antigen binding domains and uses thereof.
ATE414146T1 (en) METHODS FOR PRODUCING HELPERVIRUS-FREE PREPARATIONS OF HIGH TITRE FREE RECOMBINANT AAV VECTORS
BR112021026326A2 (en) Engineered sucrose phosphorylase, composition, polynucleotide sequence, expression vector, host cell, and method for producing an engineered sucrose phosphorylase
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
AR128475A1 (en) POLYPEPTIDES AND FUSION PROTEINS WITH TSLP BINDING AFFINITY
ATE327251T1 (en) METHOD OF REDUCING THE IMMUNOGENICITY OF STAPHYLOKINASE BY REMOVAL OF T-CELL EPITOPES
BR112018076674A2 (en) fusion protein between short-form rod derived cone viability factor and a hydrophilic peptide